We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dual Drug Repurposing: The Example of Saracatinib.
- Authors
Ramos, Raquel; Vale, Nuno
- Abstract
Saracatinib (AZD0530) is a dual Src/Abl inhibitor initially developed by AstraZeneca for cancer treatment; however, data from 2006 to 2024 reveal that this drug has been tested not only for cancer treatment, but also for the treatment of other diseases. Despite the promising pre-clinical results and the tolerability shown in phase I trials, where a maximum tolerated dose of 175 mg was defined, phase II clinical data demonstrated a low therapeutic action against several cancers and an elevated rate of adverse effects. Recently, pre-clinical research aimed at reducing the toxic effects and enhancing the therapeutic performance of saracatinib using nanoparticles and different pharmacological combinations has shown promising results. Concomitantly, saracatinib was repurposed to treat Alzheimer's disease, targeting Fyn. It showed great clinical results and required a lower daily dose than that defined for cancer treatment, 125 mg and 175 mg, respectively. In addition to Alzheimer's disease, this Src inhibitor has also been studied in relation to other health conditions such as pulmonary and liver fibrosis and even for analgesic and anti-allergic functions. Although saracatinib is still not approved by the Food and Drug Administration (FDA), the large number of alternative uses for saracatinib and the elevated number of pre-clinical and clinical trials performed suggest the huge potential of this drug for the treatment of different kinds of diseases.
- Subjects
DRUG repositioning; UNITED States. Food &; Drug Administration; ALZHEIMER'S disease; ASTRAZENECA PLC; POISONS; HEPATIC fibrosis; THERAPEUTICS; DONEPEZIL; ANTIALLERGIC agents
- Publication
International Journal of Molecular Sciences, 2024, Vol 25, Issue 8, p4565
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms25084565